Anti-CD20 Monoclonal Antibodies Market Expected to Grow at 7.75% CAGR between 2016-2020

Date: 2016-09-11

Monoclonal antibody (mAb) therapy with the anti-CD20 mAb rituximab represents one of the most important advances in the treatment of lymphoproliferative disorders in the last 30 years.

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

Future anti-CD20 Monoclonal Antibodies
The success of rituximab has stimulated considerable efforts to develop improved reagents and there are now at least 7 CD20 mAb in clinical development with many more in pre-clinical evaluation. These new mAb are engineered for potential benefits over the 1st generation rituximab, the modifications include: 2nd generation reagents where the IgG1 mAb is humanized or fully human to reduce immunogenicity, but with an unmodified Fc region; and 3rd generation mAb which are humanized and have an engineered Fc region designed to improve therapeutic performance by adapting their effector functions.

The research estimated Anti-CD20 Monoclonal Antibodies Market expected to grow at a CAGR of 7.75% over 2016-2020.

The worldwide leading players such as Bayer Schering Pharma AG, Biocon, Biogen Idec, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genmab A/S, GlaxoSmithKline Plc, GTC Biotherapeutics, Inc., Immunomedics, Inc., InNexus Biotechnology, Inc., LFB Group, Nycomed, Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Trubion Pharmaceuticals, Inc., and UCB Pharmaceutical.

Anti-CD20 Monoclonal Antibodies market share by region as following:


Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 001-510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample